Last reviewed · How we verify

NCT03823859: MATcH

Metabolomics of Thyroid Hormones

Completed Last updated 17 May 2022
What this trial tests

trial testing Indirect calorimetry in Central Hypothyroidism in 332 participants. Completed in 31 December 2021.

Timeline
12 December 2018
Primary endpoint
28 July 2021
31 December 2021

Quick facts

Lead sponsorUniversity Hospital, Basel, Switzerland
StatusCompleted
Study typeOBSERVATIONAL
Enrollment332
Start date12 December 2018
Primary completion28 July 2021
Estimated completion31 December 2021
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Basel, Switzerland

Who can join

Adults 18 to 80, any sex, with Central Hypothyroidism or Hypothyroidism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to develop a metabolome signature of thyroid hormone status. The metabolome signature could be useful in diagnosis and treatment of thyroid dysfunction diseases, especially in cases where TSH cannot be reliably used.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Indirect calorimetry

Trials testing the same drug.

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03823859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing